CR10012A - Formulaciones de proteina de fusión de Inmunoglobulina - Google Patents

Formulaciones de proteina de fusión de Inmunoglobulina

Info

Publication number
CR10012A
CR10012A CR10012A CR10012A CR10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A CR 10012 A CR10012 A CR 10012A
Authority
CR
Costa Rica
Prior art keywords
fusion protein
compositions
immunoglobulin fusion
protein formulations
disaccharide
Prior art date
Application number
CR10012A
Other languages
English (en)
Inventor
Anthony Barry
Thomas Crowley
Daniel Dixon
Jennifer Juneau
Ajay Kumar
Li Li
Nicholas Luksha
Michael Shamashkin
Erin Soley
Nicholas WARNE
Chandra Webb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10012A publication Critical patent/CR10012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a composiciones de proteínas de fusión de Ig, especialmente composiciones que incluyen una proteína de fusión de Ig, un agente de volumen, un disacárido, un tensioactivo, y un amortiguador. En un aspecto, estas composiciones son estables bajo almacenamiento a largo plazo o al menos un ciclo de congelación/descongelación. La invención también proporciona métodos de preparación de las composiciones de proteína de fusión de Ig. En un aspecto, adicional, las composiciones son liofilizadas por un proceso que incluye una etapa de recocido.
CR10012A 2005-11-22 2008-05-22 Formulaciones de proteina de fusión de Inmunoglobulina CR10012A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73927105P 2005-11-22 2005-11-22

Publications (1)

Publication Number Publication Date
CR10012A true CR10012A (es) 2008-07-29

Family

ID=37781927

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10012A CR10012A (es) 2005-11-22 2008-05-22 Formulaciones de proteina de fusión de Inmunoglobulina

Country Status (14)

Country Link
US (2) US20070237758A1 (es)
EP (1) EP1951305A1 (es)
JP (1) JP2009516692A (es)
KR (1) KR20080071192A (es)
CN (1) CN101312744A (es)
AU (1) AU2006318583A1 (es)
BR (1) BRPI0618893A2 (es)
CA (1) CA2630115A1 (es)
CR (1) CR10012A (es)
EC (1) ECSP088459A (es)
NO (1) NO20082133L (es)
RU (1) RU2008118166A (es)
SV (1) SV2009002911A (es)
WO (1) WO2007062040A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
US20080200656A1 (en) * 2007-02-16 2008-08-21 Wyeth Use Of Sucrose To Suppress Mannitol-Induced Protein Aggregation
JP5469077B2 (ja) * 2007-11-12 2014-04-09 アレス トレーディング ソシエテ アノニム Ｔａｃｉ−免疫グロブリン融合タンパク質のための調製物
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
CN101693016B (zh) * 2009-11-02 2012-07-25 北京美福源生物医药科技有限公司 通用的注射用重组人血清白蛋白融合蛋白制剂配方
ES2679819T3 (es) 2009-11-03 2018-08-31 Grifols Therapeutics Inc. Composición, método y kit para inhibidor de alfa-1 proteinasa
AU2010324839B2 (en) 2009-11-24 2015-02-19 Grifols Therapeutics Inc. Lyophilization methods, compositions, and kits
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2012101251A1 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treatment based on particular dosage regimens
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN104940926B (zh) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
GB201513010D0 (en) 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CN110607553B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法
CN111195349B (zh) * 2018-11-16 2023-02-24 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干粉制剂
MX2021008017A (es) * 2019-01-06 2021-08-05 Endo Global Aesthetics Ltd Formulaciones de colagenasa y metodos de produccion de las mismas.
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
SI2275119T1 (sl) * 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP3900664B2 (ja) * 1997-09-26 2007-04-04 株式会社ニコン 顕微鏡
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
DK2130554T3 (da) * 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
AU4314900A (en) * 1999-04-28 2000-11-17 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
ATE402716T1 (de) * 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
US20050226893A1 (en) * 2004-03-04 2005-10-13 Jennifer Juneau Lyophilization method to improve excipient crystallization

Also Published As

Publication number Publication date
CN101312744A (zh) 2008-11-26
CA2630115A1 (en) 2007-05-31
RU2008118166A (ru) 2009-12-27
JP2009516692A (ja) 2009-04-23
US20110033464A1 (en) 2011-02-10
EP1951305A1 (en) 2008-08-06
US20070237758A1 (en) 2007-10-11
KR20080071192A (ko) 2008-08-01
BRPI0618893A2 (pt) 2011-09-13
WO2007062040A1 (en) 2007-05-31
NO20082133L (no) 2008-06-16
AU2006318583A1 (en) 2007-05-31
SV2009002911A (es) 2009-03-04
ECSP088459A (es) 2008-06-30

Similar Documents

Publication Publication Date Title
CR10012A (es) Formulaciones de proteina de fusión de Inmunoglobulina
BRPI0608342A2 (pt) antìgenos recombinantes quiméricos de toxoplasma gondii
TN2012000023A1 (en) Subcutaneous anti-her2 antibody formulation
AR072058A1 (es) Composicion detergente que comprende una variante de la familia 44 de xiloglucanasas
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
MX2007010771A (es) Anfifilos peptidicos para union a heparina angiogenicos.
SG144075A1 (en) Protein stabilization formulations
PE20090738A1 (es) Formulaciones de anticuerpos
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
MX2012006831A (es) Formacion de anticuerpos.
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
AR037971A1 (es) Preparacion liofilizada que contiene un anticuerpo contra el receptor egf
ECSP077246A (es) Formulaciones Estabilizadoras
TW200700092A (en) Tigecycline compositions and methods of preparation
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
NO20062044L (no) Piscirickettsia salmonis-antigener og anvendelse derav
AR052339A1 (es) Formulaciones terapeuticas del factor de crecimiento queratinocitico
CY1114310T1 (el) Νεες ανοσοενισχυτικες συνθεσεις γλυκολιπιδιου
BRPI0613362A8 (pt) polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção
EA201100071A1 (ru) Новые композиции и способы
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
WO2006079722A3 (fr) Compositions pour la lyophilisation de proteines
MY140244A (en) Surfactant system
MX2021011530A (es) Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)